Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediPharm LabsSTU:MLZ -1.09% Return-on-Tangible-Equity is 0.04% as of Jun. 2026. The stock has 4 warning signs investors should review. Among 896 Drug Manufacturers companies, MediPharm Labs ranks worse than 81.58% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MediPharm Labs's annualized net income for the quarter that ended in Jun. 2026 was €0.01 Mil. MediPharm Labs's average shareholder tangible equity for the quarter that ended in Jun. 2026 was €21.64 Mil. Therefore, MediPharm Labs's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 0.04%.
The historical rank and industry rank for MediPharm Labs's Return-on-Tangible-Equity or its related term are showing as below:
STU:MLZ'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -67.95 Med: -33.68 Max: 2.49
Current: -13.76
During the past 9 years, MediPharm Labs's highest Return-on-Tangible-Equity was 2.49%. The lowest was -67.95%. And the median was -33.68%.
STU:MLZ's Return-on-Tangible-Equity is ranked worse than 81.58% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.575
vs STU:MLZ: -13.76
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
MediPharm Labs Return-on-Tangible-Equity Related Terms
MediPharm Labs Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for MediPharm Labs's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MLZ vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.04% mean?
MediPharm Labs (STU:MLZ) has a Return-on-Tangible-Equity of 0.04% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MediPharm Labs and its competitors. According to the industry distribution chart, MediPharm Labs ranks #731 out of 896 companies in the Drug Manufacturers industry, placing it in the top 81.6%.
Is MediPharm Labs' Return-on-Tangible-Equity too high?
MediPharm Labs' current Return-on-Tangible-Equity is 0.04%. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.58. MediPharm Labs' value of 0.04% is 99.5% below this industry median. Based on the distribution chart, MediPharm Labs ranks #731 out of 896 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does MediPharm Labs' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, MediPharm Labs ranks #731 out of 896 companies for Return-on-Tangible-Equity. This places MediPharm Labs in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.58. MediPharm Labs' value of 0.04% is 99.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.58, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediPharm Labs's current Return-on-Tangible-Equity of 0.04% is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MediPharm Labs and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediPharm Labs's current Return-on-Tangible-Equity is 0.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (STU:MLZ) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.05 — trading 13.8% above its estimated fair value. The current Return-on-Tangible-Equity is 0.04% and 99.5% below the Drug Manufacturers industry median of 7.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For MediPharm Labs (STU:MLZ), the current Return-on-Tangible-Equity is 0.04% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MLZ has been successfully added to your 
